You are here

Our science / Clinical Trials / Find a Trial / NCT01936870

Drug Use Investigation for Toviaz

Back to Search Print Save as PDF Bookmark Trial

NCT01936870

Last updated on April 10, 2018
Back to Search Print Save as PDF Bookmark Trial

FOR MORE INFORMATION
Study Location
Contact
1-800-718-1021
[email protected]
Related Links
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Overactive Bladder (OAB)
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20+ years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Patients prescribed fesoterodine (Toviaz).

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- There are no exclustion criteria

NCT01936870
Pfizer
Completed
Drug Use Investigation for Toviaz

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Advanced Search

Similar Trials

Overactive Urinary Bladder
Non-Interventional Study To Investigate Whether Information Provided To Patients Influences Their Satisfaction With Toviaz Therapy
NCT01091519
All Genders
Overactive Urinary Bladder
Special Investigation For Long Term Use Of Tolterodine (Regulatory Post Marketing Commitment Plan).
NCT00795509
All Genders
Overactive Bladder
Tolterodine Drug Use Investigation.(Post Marketing Commitment Plan)
NCT01488578
All Genders
Over Active Bladder
Post Marketing Surveillance Of Fesoterodine In Filipino Patients With Over Active Bladder
NCT01260311
All Genders
18+
Years
Multiple Sites
Drug Use Investigation for Toviaz
Drug Use Investigation For Toviaz
The purpose of this study is to collect effectiveness and safety information of fesoterodine related to their appropriate use in daily practice.
Not Provided
Observational
Observational Model: Case-Only
Time Perspective: Prospective
Not Provided
Not Provided
Probability Sample
Patients prescribed fesoterodine (Toviaz) by investigators involved in protocol A0221096.
Overactive Bladder (OAB)
Drug: Fesoterodine (Toviaz)
Fesoterodine 4 mg or 8 mg orally. Toviaz will be dosed according to labeling. The administration and duration of therapy will be determined by the treating physician to meet the patient's needs for treatment.
Fesoterodine (Toviaz)
Intervention: Drug: Fesoterodine (Toviaz)
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
2521
May 2016
May 2016   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients prescribed fesoterodine (Toviaz).

Exclusion Criteria:

  • There are no exclustion criteria
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01936870
A0221096
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
February 2017

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now